Drugs / R-(-)-gossypol acetic acid
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02697344 | Apr 2016 → Oct 2018 | plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT00544596 | Sep 2007 → Jul 2013 | small cell lung carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01003769 | Jul 2015 → Dec 2018 | B-cell chronic lymphocytic leukemia | Mayo Clinic | Terminated | No outcome recorded Stop: Business |
| Phase 22 trials | ||||||
| Phase 2 | NCT00848016 | Feb 2009 → Mar 2012 | adrenal cortex carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00773955 | Nov 2008 → Oct 2009 | small cell lung carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | R-(-)-gossypol acetic acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00773955 ↗ |
| Action | Inhibit | “R-(-)-gossypol acetic acid may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and causing the cells to die.” NCT01003769 ↗ |
| Route | Oral | “Patients receive oral R-(-)-gossypol twice daily on days 1-3” NCT00544596 ↗ |